Challenges and progress in the diagnosis of Congenital Muscular Dystrophies

Corrado Angelini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction. An accurate assessment of clinical presentation and genetic causes of congenital muscular dystrophy (CMD) has been achieved through a systematic review of literature and analysis of the current state of the art. This review reflects the diagnostic progress in the CMD field, with a recent classification based on gene discoveries. Areas covered. CMD affects children, with weakness starting in infancy or early-onset hypotonia with frequent brain involvement. Three major categories are represented and covered: cases due to merosin deficiency, cases with dystroglycan deficiency (including Fukuyama CMD, Muscle-Eye-Brain disease, and Walker-Warburg-syndrome), and collagen 6-related myopathies. The forms related to mutations in SEPN1 and LMNA genes are less frequent. Expert opinion. We present clues for CMD diagnosis either from clinical features or from muscle biopsy and brain imaging. When such studies do not yield diagnosis, new technologies such as next generation sequencing can be recommended for genetic characterization.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalExpert Opinion on Orphan Drugs
DOIs
Publication statusAccepted/In press - Feb 21 2016

Fingerprint

Muscular Dystrophies
Walker-Warburg Syndrome
Dystroglycans
Muscle Hypotonia
Expert Testimony
Genetic Association Studies
Laminin
Muscular Diseases
Neuroimaging
Collagen
Technology
Biopsy
Muscles
Mutation
Brain
Genes

Keywords

  • Collagen-6-related muscular dystrophy
  • congenital muscular dystrophy
  • dystroglycan-deficient congenital muscular dystrophy
  • Fukuyama-type congenital muscular dystrophy
  • merosin-deficient congenital muscular dystrophy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Challenges and progress in the diagnosis of Congenital Muscular Dystrophies. / Angelini, Corrado.

In: Expert Opinion on Orphan Drugs, 21.02.2016, p. 1-12.

Research output: Contribution to journalArticle

@article{76c803c5f41d4624b68090711b86e266,
title = "Challenges and progress in the diagnosis of Congenital Muscular Dystrophies",
abstract = "Introduction. An accurate assessment of clinical presentation and genetic causes of congenital muscular dystrophy (CMD) has been achieved through a systematic review of literature and analysis of the current state of the art. This review reflects the diagnostic progress in the CMD field, with a recent classification based on gene discoveries. Areas covered. CMD affects children, with weakness starting in infancy or early-onset hypotonia with frequent brain involvement. Three major categories are represented and covered: cases due to merosin deficiency, cases with dystroglycan deficiency (including Fukuyama CMD, Muscle-Eye-Brain disease, and Walker-Warburg-syndrome), and collagen 6-related myopathies. The forms related to mutations in SEPN1 and LMNA genes are less frequent. Expert opinion. We present clues for CMD diagnosis either from clinical features or from muscle biopsy and brain imaging. When such studies do not yield diagnosis, new technologies such as next generation sequencing can be recommended for genetic characterization.",
keywords = "Collagen-6-related muscular dystrophy, congenital muscular dystrophy, dystroglycan-deficient congenital muscular dystrophy, Fukuyama-type congenital muscular dystrophy, merosin-deficient congenital muscular dystrophy",
author = "Corrado Angelini",
year = "2016",
month = "2",
day = "21",
doi = "10.1517/21678707.2016.1145587",
language = "English",
pages = "1--12",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Challenges and progress in the diagnosis of Congenital Muscular Dystrophies

AU - Angelini, Corrado

PY - 2016/2/21

Y1 - 2016/2/21

N2 - Introduction. An accurate assessment of clinical presentation and genetic causes of congenital muscular dystrophy (CMD) has been achieved through a systematic review of literature and analysis of the current state of the art. This review reflects the diagnostic progress in the CMD field, with a recent classification based on gene discoveries. Areas covered. CMD affects children, with weakness starting in infancy or early-onset hypotonia with frequent brain involvement. Three major categories are represented and covered: cases due to merosin deficiency, cases with dystroglycan deficiency (including Fukuyama CMD, Muscle-Eye-Brain disease, and Walker-Warburg-syndrome), and collagen 6-related myopathies. The forms related to mutations in SEPN1 and LMNA genes are less frequent. Expert opinion. We present clues for CMD diagnosis either from clinical features or from muscle biopsy and brain imaging. When such studies do not yield diagnosis, new technologies such as next generation sequencing can be recommended for genetic characterization.

AB - Introduction. An accurate assessment of clinical presentation and genetic causes of congenital muscular dystrophy (CMD) has been achieved through a systematic review of literature and analysis of the current state of the art. This review reflects the diagnostic progress in the CMD field, with a recent classification based on gene discoveries. Areas covered. CMD affects children, with weakness starting in infancy or early-onset hypotonia with frequent brain involvement. Three major categories are represented and covered: cases due to merosin deficiency, cases with dystroglycan deficiency (including Fukuyama CMD, Muscle-Eye-Brain disease, and Walker-Warburg-syndrome), and collagen 6-related myopathies. The forms related to mutations in SEPN1 and LMNA genes are less frequent. Expert opinion. We present clues for CMD diagnosis either from clinical features or from muscle biopsy and brain imaging. When such studies do not yield diagnosis, new technologies such as next generation sequencing can be recommended for genetic characterization.

KW - Collagen-6-related muscular dystrophy

KW - congenital muscular dystrophy

KW - dystroglycan-deficient congenital muscular dystrophy

KW - Fukuyama-type congenital muscular dystrophy

KW - merosin-deficient congenital muscular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=84958756120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958756120&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1145587

DO - 10.1517/21678707.2016.1145587

M3 - Article

AN - SCOPUS:84958756120

SP - 1

EP - 12

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

ER -